197 related articles for article (PubMed ID: 35018218)
1. Induction of serine hydroxymethyltransferase 2 promotes tumorigenesis and metastasis in neuroblastoma.
Clark RA; Qiao J; Jacobson JC; Chung DH
Oncotarget; 2022; 13():32-45. PubMed ID: 35018218
[TBL] [Abstract][Full Text] [Related]
2. N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.
Kang J; Rychahou PG; Ishola TA; Mourot JM; Evers BM; Chung DH
Oncogene; 2008 Jun; 27(28):3999-4007. PubMed ID: 18278068
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Characterization of Circular RNAs in Neuroblastoma Cell Lines.
Zhang L; Zhou H; Li J; Wang X; Zhang X; Shi T; Feng G
Technol Cancer Res Treat; 2020; 19():1533033820957622. PubMed ID: 33000697
[TBL] [Abstract][Full Text] [Related]
4. Downregulating serine hydroxymethyltransferase 2 (SHMT2) suppresses tumorigenesis in human hepatocellular carcinoma.
Woo CC; Chen WC; Teo XQ; Radda GK; Lee PT
Oncotarget; 2016 Aug; 7(33):53005-53017. PubMed ID: 27391339
[TBL] [Abstract][Full Text] [Related]
5. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
[TBL] [Abstract][Full Text] [Related]
6. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
[TBL] [Abstract][Full Text] [Related]
7. Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.
Kramer M; Ribeiro D; Arsenian-Henriksson M; Deller T; Rohrer H
J Neurosci; 2016 Oct; 36(40):10425-10439. PubMed ID: 27707976
[TBL] [Abstract][Full Text] [Related]
8. SHMT2 promotes the tumorigenesis of renal cell carcinoma by regulating the m6A modification of PPAT.
Huo FC; Xie M; Zhu ZM; Zheng JN; Pei DS
Genomics; 2022 Jul; 114(4):110424. PubMed ID: 35798250
[TBL] [Abstract][Full Text] [Related]
9. Musashi-2 (MSI2) promotes neuroblastoma tumorigenesis through targeting MYC-mediated glucose-6-phosphate dehydrogenase (G6PD) transcriptional activation.
Jiang P; Zhang T; Wu B; Li X; Fu M; Xu B
Med Oncol; 2023 Oct; 40(11):332. PubMed ID: 37843625
[TBL] [Abstract][Full Text] [Related]
10. miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
Chava S; Reynolds CP; Pathania AS; Gorantla S; Poluektova LY; Coulter DW; Gupta SC; Pandey MK; Challagundla KB
Mol Oncol; 2020 Jan; 14(1):180-196. PubMed ID: 31637848
[TBL] [Abstract][Full Text] [Related]
11. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN.
Ooi CY; Carter DR; Liu B; Mayoh C; Beckers A; Lalwani A; Nagy Z; De Brouwer S; Decaesteker B; Hung TT; Norris MD; Haber M; Liu T; De Preter K; Speleman F; Cheung BB; Marshall GM
Cancer Res; 2018 Jun; 78(12):3122-3134. PubMed ID: 29610116
[TBL] [Abstract][Full Text] [Related]
12. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
13. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
[TBL] [Abstract][Full Text] [Related]
14. Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN.
Zhang X; Cong X; Jin X; Liu Y; Zhang T; Fan X; Shi X; Zhang X; Wang X; Yang YG; Dai X
Cell Death Dis; 2023 Aug; 14(8):504. PubMed ID: 37543638
[TBL] [Abstract][Full Text] [Related]
15. SHMT2 promotes cell viability and inhibits ROS-dependent, mitochondrial-mediated apoptosis via the intrinsic signaling pathway in bladder cancer cells.
Zhang Y; Liu Z; Wang X; Jian H; Xiao H; Wen T
Cancer Gene Ther; 2022 Oct; 29(10):1514-1527. PubMed ID: 35422087
[TBL] [Abstract][Full Text] [Related]
16. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.
Xu Y; Chen X; Lin L; Chen H; Yu S; Li D
Biochimie; 2017 Aug; 139():1-8. PubMed ID: 28456710
[TBL] [Abstract][Full Text] [Related]
18. Interplay between MycN and c-Myc regulates radioresistance and cancer stem cell phenotype in neuroblastoma upon glutamine deprivation.
Le Grand M; Mukha A; Püschel J; Valli E; Kamili A; Vittorio O; Dubrovska A; Kavallaris M
Theranostics; 2020; 10(14):6411-6429. PubMed ID: 32483461
[TBL] [Abstract][Full Text] [Related]
19. TAF1D promotes proliferation by transcriptionally activating G2/M phase-related genes in MYCN-amplified neuroblastoma.
Zhang X; Zhan S; Guan X; Zhang Y; Lu J; Yu Y; Jin Y; Yang Y; Chu P; Hong E; Yang H; Ren H; Geng D; Wang Y; Zhou P; Guo Y; Chang Y
Cancer Sci; 2023 Jul; 114(7):2860-2870. PubMed ID: 37094904
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic SHMT2 drives the progression and metastasis of colorectal cancer by inhibiting β-catenin degradation.
Liu C; Wang L; Liu X; Tan Y; Tao L; Xiao Y; Deng P; Wang H; Deng Q; Lin Y; Jie H; Zhang H; Zhang J; Peng Y; Zhang H; Zhou Z; Sun Q; Cen X; Zhao Y
Theranostics; 2021; 11(6):2966-2986. PubMed ID: 33456583
[No Abstract] [Full Text] [Related]
[Next] [New Search]
